Moderna Inc (MRNA) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

Total Revenue Chart for Moderna Inc

Moderna Inc (MRNA) revenue for FY2025 was USD 1.9B, a -39.2% change from FY2024. Moderna Inc's revenue grew from USD 500.0K in 2014 to USD 1.9B in 2025 (388700.0% over 11 years). Earnings per share moved from USD -0.02 in 2015 to USD 20.10 in 2022. Revenue compound annual growth rate: 5-year CAGR of 47.9%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$21.50B
Implied Share Price
$53.86
Enterprise Value
$17.90B
Revenue (TTM)
$2.23B
EBITDA
-$2.20B
Profit Margin
-141.43%
Trailing P/E
—
Forward P/E
23.04
Price/Book (MRQ)
3.22
Price/Sales (TTM)
9.65
EV/EBITDA
4.64
EV/Revenue
8.10
Dividend Yield
—
Book Value
$18.66
Free Cash Flow (FY2025)
-$2.06B
Free Cash Flow Yield
-9.60%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.